Lipidomics-based natural products for chronic kidney disease treatment

Area of Science:

• Biochemistry
• Nephrology
• Metabolomics

Background:

• Chronic kidney disease (CKD) is a prevalent global health problem, exacerbated by rising rates of diabetes, hypertension, and obesity.
• Current biomarkers for kidney function lack the sensitivity and specificity for early CKD detection and monitoring.
• Dyslipidemia is a characteristic feature of CKD, highlighting the role of lipids in disease progression.

Purpose of the Study:

• To explore the role of lipids and lipidomics in chronic kidney disease.
• To identify novel lipid-based biomarkers for early CKD diagnosis and monitoring.
• To investigate natural products derived from lipidomics for potential CKD therapeutic applications.

Main Methods:

• Utilizing advanced mass spectrometry (MS)-based lipidomics platforms for comprehensive lipid analysis in biological samples.
• Analyzing lipidome alterations associated with metabolic disorders in the context of CKD.
• Identifying and characterizing novel biomarkers through lipidomics approaches.

Main Results:

• Lipidomics has revealed significant changes in the lipidome associated with CKD.
• Novel biomarkers for kidney diseases have been identified using lipidomics.
• Natural products with therapeutic potential for CKD have been discovered through lipidomics.

Conclusions:

• Lipidomics offers a powerful approach for understanding CKD pathogenesis and identifying new therapeutic targets.
• Novel lipid biomarkers can improve early diagnosis and monitoring of CKD progression.
• Natural products identified via lipidomics show promise for improving CKD outcomes from a lipidomic perspective.